NanoViricides is trading 14.86% lower at $1.26 before the October 21, 2026 open, with no clear overnight company-specific catalyst identified. - It closed at $1.48 on October 20, after rising 13.85% in the prior session. - An October 20 company announcement said NV-387 was well tolerated in a juvenile-mouse safety study, with no mortality or treatment-related adverse findings. The news accompanied the prior session’s advance but does not explain the pre-market decline.